Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis

Overview of attention for article published in Frontiers in oncology, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Readers on

mendeley: 4 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 24,024 followers.

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis https://t.co/ulU7G5Q3cq https://t.co/l0w5hS0sYT

01 Nov 2022

Reply Repost Favourite

RT @FrontOncology: New research: Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metas…

01 Nov 2022

Reply Repost Favourite

New research: Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis: Background Osteosarcoma commonly… https://t.co/X

01 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.